1,173,286 Shares in Illumina, Inc. $ILMN Purchased by Legal & General Group Plc

Legal & General Group Plc bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,173,286 shares of the life sciences company’s stock, valued at approximately $206,299,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Empowered Funds LLC grew its stake in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares in the last quarter. Sivia Capital Partners LLC bought a new position in Illumina during the second quarter worth $621,000. CW Advisors LLC acquired a new position in shares of Illumina during the second quarter valued at about $275,000. Marshall Wace LLP lifted its holdings in shares of Illumina by 49.0% during the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock worth $5,691,000 after acquiring an additional 19,618 shares during the period. Finally, Cresset Asset Management LLC boosted its holdings in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock valued at $706,000 after purchasing an additional 1,748 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ILMN shares. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. JPMorgan Chase & Co. raised their target price on shares of Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Piper Sandler restated an “overweight” rating and set a $225.00 price objective (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Finally, Guggenheim raised their target price on shares of Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Illumina presently has an average rating of “Hold” and an average price target of $188.40.

Illumina Stock Down 0.1%

NASDAQ ILMN opened at $224.84 on Thursday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 1-year low of $88.00 and a 1-year high of $227.70. The company has a market cap of $33.95 billion, a price-to-earnings ratio of 41.95, a PEG ratio of 3.17 and a beta of 1.45. The company has a 50 day moving average of $191.66 and a 200-day moving average of $154.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter last year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Insider Transactions at Illumina

In related news, SVP Patricia Leckman sold 783 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $162.59, for a total value of $127,307.97. Following the completion of the transaction, the senior vice president owned 21,259 shares in the company, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the transaction, the director owned 2,372,694 shares in the company, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 1,874,458 shares of company stock worth $367,996,424. 2.90% of the stock is owned by corporate insiders.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.